HIKAL
|
HIKAL Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 7.35 | 5.64 | 6.36 | 13.02 | 10.80 |
| CEPS(Rs) | 18.23 | 15.16 | 15.20 | 20.78 | 17.71 |
| DPS(Rs) | 1.40 | 1.20 | 1.20 | 1.60 | 2.00 |
| Book NAV/Share(Rs) | 102.21 | 96.17 | 91.93 | 86.62 | 75.70 |
| Tax Rate(%) | 26.66 | 27.12 | 25.61 | 26.56 | 35.50 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 17.66 | 14.96 | 12.71 | 17.53 | 18.77 |
| EBIT Margin(%) | 10.70 | 8.51 | 7.59 | 12.86 | 14.10 |
| Pre Tax Margin(%) | 6.66 | 5.35 | 5.21 | 11.25 | 12.00 |
| PAT Margin (%) | 4.88 | 3.90 | 3.87 | 8.26 | 7.74 |
| Cash Profit Margin (%) | 12.11 | 10.49 | 9.26 | 13.19 | 12.69 |
| Performance Ratios | |||||
| ROA(%) | 3.26 | 2.70 | 3.33 | 7.39 | 6.84 |
| ROE(%) | 7.41 | 6.00 | 7.12 | 16.04 | 15.22 |
| ROCE(%) | 9.88 | 7.82 | 8.47 | 15.21 | 16.15 |
| Asset Turnover(x) | 0.67 | 0.69 | 0.86 | 0.89 | 0.88 |
| Sales/Fixed Asset(x) | 0.92 | 1.06 | 1.37 | 1.54 | 1.57 |
| Working Capital/Sales(x) | 9.03 | 8.50 | 7.29 | 9.96 | 7.76 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.08 | 0.94 | 0.73 | 0.65 | 0.64 |
| Receivable days | 105.26 | 101.45 | 79.34 | 86.73 | 87.62 |
| Inventory Days | 62.63 | 63.45 | 58.25 | 55.96 | 61.44 |
| Payable days | 127.05 | 131.02 | 92.70 | 87.68 | 86.55 |
| Valuation Parameters | |||||
| PER(x) | 54.42 | 46.99 | 44.34 | 30.92 | 13.29 |
| PCE(x) | 21.94 | 17.47 | 18.55 | 19.37 | 8.10 |
| Price/Book(x) | 3.91 | 2.75 | 3.07 | 4.65 | 1.90 |
| Yield(%) | 0.35 | 0.45 | 0.43 | 0.40 | 1.39 |
| EV/Net Sales(x) | 3.06 | 2.28 | 2.06 | 2.88 | 1.36 |
| EV/Core EBITDA(x) | 17.05 | 15.08 | 15.87 | 16.17 | 7.14 |
| EV/EBIT(x) | 28.57 | 26.76 | 27.13 | 22.37 | 9.65 |
| EV/CE(x) | 2.81 | 2.03 | 2.21 | 3.21 | 1.52 |
| M Cap / Sales | 2.66 | 1.83 | 1.72 | 2.55 | 1.03 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 4.21 | -11.79 | 4.13 | 12.92 | 14.14 |
| Core EBITDA Growth(%) | 23.71 | 2.67 | -24.02 | 5.36 | 18.42 |
| EBIT Growth(%) | 31.01 | -1.02 | -38.56 | 2.95 | 35.55 |
| PAT Growth(%) | 30.46 | -11.20 | -51.16 | 20.55 | 57.68 |
| EPS Growth(%) | 30.46 | -11.35 | -51.16 | 20.55 | 57.68 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.60 | 0.69 | 0.66 | 0.63 | 0.65 |
| Current Ratio(x) | 1.20 | 1.23 | 1.42 | 1.24 | 1.32 |
| Quick Ratio(x) | 0.87 | 0.90 | 0.94 | 0.84 | 0.94 |
| Interest Cover(x) | 2.65 | 2.69 | 3.19 | 8.00 | 6.70 |
| Total Debt/Mcap(x) | 0.15 | 0.25 | 0.22 | 0.14 | 0.34 |
Compare Financial Ratios of peers of HIKAL
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| HIKAL | ₹3,015.3 Cr | 1.8% | -4.1% | -33.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹409,626.0 Cr | 1.2% | 4.4% | -9.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹180,669.0 Cr | 5.8% | 19.2% | 16.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹122,793.0 Cr | 1.4% | 1.8% | 10.8% | Stock Analytics | |
| CIPLA | ₹122,103.0 Cr | -3.7% | -0.2% | 1.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,857.4 Cr | -7.3% | -4% | -6.1% | Stock Analytics | |
HIKAL Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| HIKAL | 1.8% |
-4.1% |
-33.1% |
| SENSEX | -0.9% |
4.6% |
5% |
You may also like the below Video Courses
